Researchers at Cincinnati Children's have identified a potential new way to relieve chronic pain linked to neurofibromatosis ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mirdametinib is an investigational mitogen-activated ...

Health experts underscore that early detection of Neurofibromatosis Type 1 (NF1) signs and symptoms is essential for proper patient management and timely specialist referrals. Subsequent monitoring is ...

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin. Basal ...

Scientists from the National Cancer Institute’s (NCI) Center for Cancer Research, and the Washington University School of Medicine in St. Louis have developed a blood test that, they believe, could ...

What Is Koselugo, and Why Does It Matter? Koselugo (selumetinib) is an oral medicine that helps slow the growth of certain tumors. The FDA has approved it for adults with neurofibromatosis type 1 (NF1 ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

Please provide your email address to receive an email when new articles are posted on . Severe auditory dysfunction was a common neurobiological feature of neurofibromatosis type 1, according to ...

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer ...

Panelists discuss how neurofibromatosis type 1 (NF1) is typically diagnosed in early childhood using National Institutes of Health (NIH) clinical criteria, with genetic testing supporting unclear ...